Clinical Trial Update: Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG) [NA]

View source ↗

Summary

This clinical trial update notes termination of the HN2301 study in refractory myasthenia gravis and mentions efficacy and safety data, though details are not p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• HN2301 (HN2301)

Snippet

Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Conditions: Refractory Myasthenia Gravis | NA | Status: TERMINATED